MEDIA RELEASE PR41879
Perrigo Announces Australian Approval of Polyethylene Glycol 3350
ALLEGAN, Mich., Oct. 25 /PRNewswire-AsiaNet/ --
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received certification from the Therapeutic
Goods Association for its U.S. manufactured product, Polyethylene Glycol 3350, Powder for Solution for sale in the
Australian market. The product is listed on the Pharmaceutical Benefits Scheme (PBS) which makes the product
available to more consumers through direct prescription substitution. This is the first step for Perrigo marketing its U.S.
portfolio of products across the globe.
The product will be marketed under store brand labels and will compete with Norgine Pharmaceuticals' Movicol(R),
indicated for the treatment of occasional constipation.
Perrigo's Chairman and CEO Joseph C. Papa stated, "This is example of Perrigo's commitment to expanding our
global footprint by bringing our U.S. store brand product portfolio to new markets. Perrigo is the largest store brand
manufacturer of quality, affordable over-the-counter healthcare products in the United States, United Kingdom, Mexico
and soon to be Australia."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic
prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The
Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The
Company's primary markets and locations of manufacturing and logistics operations are the United States, Australia,
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements
relate to future events or the Company's future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the
Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In
some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should,"
"expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The
Company has based these forward-looking statements on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable,
such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of
which are beyond the Company's control. These and other important factors, including those discussed under "Risk
Factors" in the Company's Form 10-K for the year ended June 27, 2009, as well as the Company's subsequent filings
with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ
materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this
press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the
Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
SOURCE: Perrigo Company
CONTACT: Arthur J. Shannon,
Vice President,
Investor Relations and Communication,
+1-269-686-1709,
ajshannon@perrigo.com;
or Daniel B. Willard, Manager,
Investor Relations and Communication,
+1-269-686-1597,
dbwillard@perrigo.com
NEWS 
